Drug Regulation and Oversight, from Local to Global

被引:1
|
作者
Babyar, Julie [1 ]
机构
[1] 415 Herondo St,Apt 332, Hermosa Beach, CA 90254 USA
关键词
Drug regulation; Regulatory medicine; Drug approval; International drug harmonization; Global medicine regulation; APPROVAL;
D O I
10.1007/s12247-017-9280-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this perspective piece is to address the potential for drug and medical product innovation through sound regulation and strengthened international harmonization. Current literature, recommendations and guidelines in regulatory agencies assisted in this perspective review. Multiple guidelines and recommendations provide for strategic planning and process improvement capabilities at local, national and international levels. Seeking best practice starts with identifying and improving individual nation drug regulatory bodies, including the US Food and Drug Administration (FDA). Inefficiency causes and process improvement solutions have been suggested and outlined in strategic plans at the FDA as well as with multiple stakeholder organizations and public-private partnerships. Cohesively, these groups should be tasked with formal, consistent updates on improvement as well as ongoing supportive research and evaluation of the changes implemented. Simultaneously, the international community has a tremendous opportunity to act on best practice for drug and medical product innovation by aligning sound and consistent approach to regulation.
引用
收藏
页码:185 / 187
页数:3
相关论文
共 50 条
  • [1] Drug Regulation and Oversight, from Local to Global
    Julie Babyar
    Journal of Pharmaceutical Innovation, 2017, 12 : 185 - 187
  • [2] The advisory process for anticancer drug regulation: a global perspective
    Farrell, AT
    Papadouli, I
    Hori, A
    Harczy, M
    Harrison, B
    Asakura, W
    Marty, M
    Dagher, R
    Pazdur, R
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 889 - 896
  • [4] Value for money of drug regulation
    Bouvy, Jacoline C.
    Koopmanschap, Marc A.
    Schellekens, Huub
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 247 - 249
  • [5] The reliability of evidential pluralism in drug regulation
    Andreoletti, Mattia
    Perez-Gonzalez, Saul
    SYNTHESE, 2024, 204 (01)
  • [6] Quantitative clinical pharmacology is transforming drug regulation
    Peck, Carl C.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (06) : 617 - 628
  • [8] Quantitative clinical pharmacology is transforming drug regulation
    Carl C. Peck
    Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37 : 617 - 628
  • [9] Clinical toxicology and drug regulation: A United Kingdom perspective
    Waring, W. Stephen
    McGettigan, Patricia
    CLINICAL TOXICOLOGY, 2011, 49 (06) : 452 - 456
  • [10] Role of autophagy in drug resistance and regulation of osteosarcoma (Review)
    Pu, Yanchuan
    Wang, Jin
    Wang, Shizhong
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (03)